Despite the influx of adalimumab biosimilars entering the market in 2023, Humira remains on top. As of January 2024, both high and low concentrations of Humira, the originator adalimumab product, are nearly universally covered by Medicare Part D plans, while only half of these plans covered adalimumab biosimilars…
